TCGA-OR-A5JC-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.299
- MYC_TARGETS_V2+0.246
- NOTCH_SIGNALING+0.231
- MYC_TARGETS_V1+0.204
- DNA_REPAIR+0.159
- E2F_TARGETS+0.140
- OXIDATIVE_PHOSPHORYLATION+0.128
- UV_RESPONSE_UP+0.124
- ALLOGRAFT_REJECTION+0.119
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.116
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.325
- HYPOXIA-0.246
- COAGULATION-0.242
- HEME_METABOLISM-0.237
- IL6_JAK_STAT3_SIGNALING-0.228
- TNFA_SIGNALING_VIA_NFKB-0.197
- MTORC1_SIGNALING-0.188
- BILE_ACID_METABOLISM-0.181
- MITOTIC_SPINDLE-0.172
- PROTEIN_SECRETION-0.151
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 10489620-bd98-43ab-9d5f-8ae0c0b1ff7a | — | — | 0.682 |
| 2 | SRR4195683 | — | — | 0.659 |
| 3 | R175 | — | — | 0.655 |
| 4 | 90dab784-fa67-4b32-9489-6cd1cb6365ac | — | — | 0.640 |
| 5 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.638 |
| 6 | SRR2016966 | — | — | 0.630 |
| 7 | 3aa50a90-3e9b-4b72-aa81-7ea3bc7861a3 | — | — | 0.628 |
| 8 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.625 |
| 9 | 784b2763-b9be-4b7f-84b0-f5ec6f784717 | — | — | 0.619 |
| 10 | TCGA-LL-A7T0-01A-31R-A352-07 | — | B | 0.618 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.299 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.246 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.231 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.204 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.159 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.128 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.124 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.119 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.116 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.084 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.062 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.058 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.052 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.035 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.003 | Inavolisib | — uncovered |